Cited 110 times in
Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.contributor.author | 김호근 | - |
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2015-06-10T12:04:48Z | - |
dc.date.available | 2015-06-10T12:04:48Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109153 | - |
dc.description.abstract | PURPOSE: We investigated whether an armed viral platform, where lytic property of a viral infection is coupled to viral-mediated delivery of therapeutic genes, could increase the therapeutic potential of a viral-based therapy. EXPERIMENTAL DESIGN: We generated interleukin (IL)-12-expressing oncolytic adenovirus (YKL-IL-12) and IL-12- and B7-1-expressing (YKL-IL12/B7) oncolytic adenovirus. Therapeutic efficacy of these newly engineered adenoviruses was then evaluated in vivo using an immunocompetent mouse bearing murine melanoma B16-F10 tumors. Overall survival was assessed with the Kaplan-Meier method. The induction of immune cell cytotoxicity was assessed by CTL assay, IFN-gamma enzyme-linked immunospot assay, and immunohistochemical studies. RESULTS: YKL-IL12/B7 oncolytic adenovirus, expressing both IL-12 and B7-1, showed a higher incidence of complete tumor regression compared with the analogous oncolytic adenovirus, YKL-1, or IL-12-expressing, YKL-IL12. Significant survival advantage was also seen in response to YKL-IL12/B7. Moreover, IL-12 and IFN-gamma levels produced in tumors treated with YKL-IL12/B7 was significantly greater than those treated with YKL-IL12. The enhanced survival advantage was mediated by the induction of immune cell cytotoxicity. In agreement with these results, massive infiltration of CD4(+) and CD8(+) T cells into tissues surrounding the necrotic area of the tumor was observed following in situ delivery of YKL-IL12/B7. CONCLUSION: Combination of oncolysis and the enhancement of antitumor immune response by oncolytic adenovirus expressing both IL-12 and B7-1 elicits potent antitumor effect and survival advantage. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 5859~5868 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenoviridae/genetics* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | B7-1 Antigen/genetics | - |
dc.subject.MESH | B7-1 Antigen/immunology | - |
dc.subject.MESH | B7-1 Antigen/metabolism* | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Gene Expression | - |
dc.subject.MESH | Genetic Therapy/methods* | - |
dc.subject.MESH | Genetic Vectors/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Interferon-gamma/metabolism | - |
dc.subject.MESH | Interleukin-12/genetics | - |
dc.subject.MESH | Interleukin-12/immunology | - |
dc.subject.MESH | Interleukin-12/metabolism* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melanoma, Experimental/immunology | - |
dc.subject.MESH | Melanoma, Experimental/therapy* | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Mice, Nude | - |
dc.subject.MESH | Neoplasms/immunology | - |
dc.subject.MESH | Neoplasms/therapy* | - |
dc.subject.MESH | Oncolytic Virotherapy/methods* | - |
dc.subject.MESH | T-Lymphocytes/immunology | - |
dc.subject.MESH | Tumor Cells, Cultured | - |
dc.subject.MESH | Virus Replication/drug effects | - |
dc.title | Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Young-Sook Lee | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Kyung-Ju Choi | - |
dc.contributor.googleauthor | Il-Kyu Choi | - |
dc.contributor.googleauthor | Hoguen Kim | - |
dc.contributor.googleauthor | Sungae Cho | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Chae-Ok Yun | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-06-0935 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01183 | - |
dc.contributor.localId | A02614 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 17020994 | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Kim, Ho Keun | - |
dc.contributor.alternativeName | Yun, Chae Ok | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Ho Keun | - |
dc.contributor.affiliatedAuthor | Yun, Chae Ok | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 12 | - |
dc.citation.number | 19 | - |
dc.citation.startPage | 5859 | - |
dc.citation.endPage | 5868 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.12(19) : 5859-5868, 2006 | - |
dc.identifier.rimsid | 50625 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.